Loading...
Trimethoprim/sulfamethoxazole (TMP/SMX) use is associated with excess risk for hyperkalemia and related adverse events in patients who take angiotensin-converting–enzyme inhibitors, angiotensin-receptor blockers (NEJM JW Gen Med Sep 1 2010 and JAMA Intern Med 2010; 170:1045; NEJM JW Gen Med Dec 15 2014 and BMJ 2014; 349:6196), or spironolactone (NEJM JW Gen Med Nov 1 2011 and BMJ 2011; 343:5228). However, whether TMP confers risk for hyperkalemia when it is used without SMX and in the absence of renin-angiotensin system blockers is unknown. In the U.K., TMP often is prescribed without SMX, giving researchers an opportunity to clarify this issue in a cohort of 180,000 patients (age, ≥65) who experienced at least one urinary tract infection (…